EDWARDS LIFESCIENCES CORP (EW)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for EW
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| EW | Chief Executive Officer, Edwards Lifesciences Corporation; CEO; Director and Chief Executive Officer | 58 | ["Chief Executive Officer at Edwards Lifesciences Corporation since 2023", "President from January 2023 to May 2023", "Corporate Vice President, Transcatheter Mitral and Tricuspid Therapies (TMTT) from 2018 to 2023", "Vice President then Corporate Vice President, Surgical Structural Heart from 2015 to 2018", "Held various roles at Johnson & Johnson for nearly 20 years, including worldwide President of one of the company's divisions", "Expert in strategy development and disruptive technologies in medical technology"] | [] | 2026 |
Biography sourced from the proxy statement filing.
CEO, Edwards Lifesciences Corporation Age: 58 Director Since: 2023 Edwards Board Role: Director Select Professional Experience and Highlights: Edwards Lifesciences Corporation, since 2015 Chief Executive Officer, since 2023 President, from January 2023 to May 2023 Corporate Vice President, Transcatheter Mitral and Tricuspid Therapies (TMTT), from 2018 to 2023 Vice President then Corporate Vice President, Surgical Structural Heart, from 2015 to 2018 Johnson & Johnson, from 1995 to 2014 Held a variety of roles with increasing levels of responsibility for nearly 20 years, including worldwide President of one of the company's divisions Select Skills and Qualifications: With a career spanning more than three decades in medical technology, Mr. Zovighian has led global businesses in several countries across two world-class companies, demonstrating strengths in strategy development, innovation and adoption of disruptive technologies. During his tenure as CEO, Mr. Zovighian has distinguished the Edwards strategy by spearheading the divestment of the Critical Care business and sharpening the company s focus on structural heart disease. The strategy has been advanced through continued differentiated investment in innovative therapies to solve large and complex patient needs and pioneering therapeutic categories of care. Mr. Zovighian joined Edwards Lifesciences in January 2015 as vice president and general manager of the Surgical Structural Heart business, and later served as corporate vice president of the surgical business from 2016 until he became corporate vice president responsible for the company s Transcatheter Mitral and Tricuspid Therapies (TMTT) business in January 2018. Mr. Zovighian established a global organization focused on developing a portfolio of therapies designed to change the standard of care for mitral and tricuspid patients. Prior to joining Edwards, Mr. Zovighian held roles with increasing levels of responsibility at Johnson & Johnson for nearly 20 years, including worldwide president of one of the company s divisions. Mr. Zovighian serves as an advisory board member for the Leonard D. Schaeffer Center for Health Policy & Economics at the University of Southern California.